Literature DB >> 21106938

MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism.

Sandra Kraemer1, Hongqi Lue, Alma Zernecke, Aphrodite Kapurniotu, Erika Andreetto, Ronald Frank, Birgitt Lennartz, Christian Weber, Jürgen Bernhagen.   

Abstract

Macrophage migration inhibitory factor (MIF) is a cytokine that mediates inflammatory diseases. MIF promotes atherogenic leukocyte recruitment through a promiscuous, yet highly affine, interaction with CXCR2 and CXCR4. Binding to CXCR2 is dependent on a pseudo-(E)LR motif in MIF, but a second interaction site has been elusive. Here we identified an N-like loop in MIF, suggesting that MIF binding to CXCR2 follows the 2-site binding mode of bona fide chemokines. For MIF, the model predicts interactions between the N-like loop and the CXCR2 N domain (site 1) and pseudo-(E)LR and extracellular loops (ELs) of CXCR2 (site 2). Applying biophysical and peptide array analysis, we demonstrated an interaction between MIF and the CXCR2 N domain, which was pseudo-(E)LR independent. Peptide array analysis also indicated that the pseudo-(E)LR motif is responsible for MIF binding to EL2 and 3. Notably, peptides MIF-(40-49) and MIF-(47-56), representing N-like-loop-derived peptides, but not a scrambled control peptide, significantly blocked MIF/CXCR2 binding, MIF-mediated monocyte arrest under flow on aortic endothelial cells in vitro (IC(50): 1.24×10(-6) M), and MIF-dependent monocyte adhesion to atherosclerotic mouse carotid arteries in vivo. Thus, the N-like loop in MIF is critical for MIF's noncognate interaction with CXCR2 and proatherogenic functions. The 2-site binding model that explains chemokine receptor activation also applies to MIF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106938     DOI: 10.1096/fj.10-168559

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

Review 1.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 2.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 4.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

5.  Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: EVIDENCE FOR PARTIAL ALLOSTERIC AGONISM IN COMPARISON WITH CXCL12 CHEMOKINE.

Authors:  Deepa Rajasekaran; Sabine Gröning; Corinna Schmitz; Swen Zierow; Natalie Drucker; Maria Bakou; Kristian Kohl; André Mertens; Hongqi Lue; Christian Weber; Annie Xiao; Gary Luker; Aphrodite Kapurniotu; Elias Lolis; Jürgen Bernhagen
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

6.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 7.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

8.  A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF).

Authors:  Fengwei Bai; Oluwatoyin A Asojo; Pier Cirillo; Mihai Ciustea; Michel Ledizet; Paul A Aristoff; Lin Leng; Raymond A Koski; Thomas J Powell; Richard Bucala; Karen G Anthony
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion.

Authors:  Elisa A Liehn; Isabella Kanzler; Simone Konschalla; Andreas Kroh; Sakine Simsekyilmaz; Tolga Taha Sönmez; Richard Bucala; Jürgen Bernhagen; Christian Weber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-18       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.